Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hae.12968 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease.
Emerg Microbes Infect
December 2025
State Key Laboratory of Pathogenic Microorganisms, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, People's Republic of China.
Marburg virus disease (MVD) is a severe infectious disease caused by the Marburg virus (MARV), posing a significant threat to humans. MARV needs to be operated under strict biosafety Level 4 (BSL-4) laboratory conditions. Therefore, accessible and practical animal models are urgently needed to advance prophylactic and therapeutic strategies for MARV.
View Article and Find Full Text PDFThe Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related.
Pediatr Blood Cancer
February 2025
National Hemophilia Center, Sheba Medical center, Tel Hashomer, Israel.
Introduction: Hemophilia A (HA) therapy poses a significant healthcare burden. In recent years, emicizumab has been approved for prophylaxis. The current study explores the impact of transitioning to emicizumab on emergency department (ED) visits and hospitalizations in pediatric and adult HA patients.
View Article and Find Full Text PDFAcquired hemophilia A as a disease of the elderly: A comprehensive review of epidemiology, pathogenesis, and novel therapy.
Geroscience
September 2024
Doctoral College, Health Sciences Program, Semmelweis University, Budapest, Hungary.
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by the development of neutralizing autoantibodies (inhibitors) against coagulation factor VIII (FVIII). This review provides an in-depth exploration of AHA, covering its epidemiology, pathogenesis, clinical presentation, diagnosis, complications, and treatment strategies, focusing on recent advancements. AHA can manifest in both men and women with no prior bleeding history.
View Article and Find Full Text PDFThe association between unemployment and treatment among adults with hemophilia.
Res Pract Thromb Haemost
July 2024
Department of Haematology, Oslo University Hospital Rikshospitalet, Rikshospitalet, Norway.
Background: People with hemophilia often experience pain and suffer from comorbidities related to their bleeding disorder. Consequently, unemployment due to disability is prevalent among people with hemophilia.
Objectives: To explore associations between unemployment due to disability and treatment while adjusting for known risk factors for unemployment.
Outcome measures in hemophilia: current and future perspectives.
Expert Rev Hematol
July 2024
Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy.
Introduction: Hemophilia can detrimentally affect patients' quality of life and likelihood of survival. In the evolving landscape of therapies, the therapeutic gain of each treatment must be understood to accurately position it in the therapeutic armamentarium. Accordingly, appropriate outcomes must be measured with appropriate tools.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!